Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
Linda Butros, Koh Boayue, Prasad MathewThe University of New Mexico, Albuquerque, New Mexico, USAAbstract: Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding...
Main Authors: | Butros L, Boayue K, Mathew P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-05-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/current-difficulties-and-recent-advances-in-bypass-therapy-for-the-man-a7437 |
Similar Items
-
HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa
by: Dušan Andoljšek, et al.
Published: (2004-12-01) -
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
by: Lentz SR, et al.
Published: (2014-01-01) -
Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
by: Francesco Demartis, et al.
Published: (2017-07-01) -
Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
by: Egon Persson, et al.
Published: (2019-10-01) -
Gene Therapy in Hemophilia: Recent Advances
by: E. Carlos Rodríguez-Merchán, et al.
Published: (2021-07-01)